NEW YORK – Illumina and Qiagen today announced a 15-year partnership to develop next-generation sequencing-based in vitro diagnostic kits, including companion diagnostics. The deal accompanied announcements that Qiagen CEO Peer Schatz would step down and that the firm has lowered its third quarter sales growth expectations.